For biosimilars to be embraced and fully successful in the market, companies need to understand patients’ perceptions of these follow-on biologics so they can better, and more proactively, address concerns and provide educational resources.
In this white paper, our experts break down the results of qualitative and quantitative surveys of patients about their opinions and experiences with biosimilars to better understand and address barriers to acceptance of biosimilars in the marketplace.
Download the white paper below
